Huahai Pharmaceutical (600521.SH): Resicibizumab injection approved for drug registration

Zhitong Finance App News, Huahai Pharmaceutical (600521.SH) issued an announcement. Recently, the company learned from the China Drug Administration's website that the State Drug Administration approved the listing of rexiqibizumab injection (trade name: Huayijing) declared by Shanghai Huaotai Biopharmaceutical Co., Ltd. (a holding subsidiary of the company, “Huaotai”) for the treatment of generalized pustular psoriatic attacks in adults (body weight ≥40 kg).

Currently, no targeted IL-36R antibodies developed by domestic companies have been approved for marketing globally. As the first self-developed anti-IL-36R antibody in China, Resicibizumab injection can exert anti-inflammatory biological effects by inhibiting the IL-36 pathway. According to research analysis results, compared to placebo, skin pustules in patients with GPP episodes in week 1 after a single intravenous administration of resicibimab injection were clearly removed, reaching the main study end point set by the protocol. The safety performance was good, and no new safety signals were found. Up to now, the company has invested a total of about RMB 259.15 million in R&D in the resizibizumab injection project.